Key Highlights

  • Roivant Sciences (NASDAQ:ROIV) reported USD 31.0 million of net product Revenue from LISRAYA in its first five weeks on the US market, in quarterly results released on November 9, 2026.
  • Total revenue for the quarter to September 30 was USD 35.1 million, including USD 4.2 million of license and milestone revenue.
  • Cash, equivalents and marketable securities were about USD 4.2 billion, and the company bought back 2.1 million shares for about USD 72.5 million during the quarter.
  • Pipeline updates included a positive registrational-stage rheumatoid arthritis result for IMVT-1402 and positive Phase 3 uveitis data for brepocitinib, the drug sold as LISRAYA.

The Launch

LISRAYA, the Brand name for brepocitinib, won FDA approval in August 2026 and became commercially available in the US the same month. Five weeks of sales generated USD 31.0 million of net product revenue for Roivant Sciences (NASDAQ:ROIV), a strong figure for a new specialty drug in its first partial quarter. Launch spending pushed selling, general and administrative costs up to USD 154.1 million from USD 143.1 million, while research costs fell to USD 145.7 million from USD 164.6 million. The loss from continuing operations was USD 153.0 million, or USD 0.29 per share, and the net loss attributable to Roivant was USD 191.6 million. That included USD 95.9 million of distributions to holders of awards in its Genevant unit, which cost USD 0.13 per share. The adjusted loss from continuing operations was USD 133.4 million. Results were ahead of market expectations, and the shares rose after the report.

The Pipeline

Roivant's majority-owned Immunovant unit reported that a 600 milligram dose of IMVT-1402, an FcRn inhibitor, met the primary endpoint in a potentially registrational study in difficult-to-treat rheumatoid arthritis. At week 28, 92.5% of patients on that dose achieved an ACR20 response against 75.6% on placebo. A 300 milligram dose did not separate from placebo, and no serious adverse events were seen in that period. FDA discussions are planned later this year. Brepocitinib also met its primary and all key secondary endpoints in two Phase 3 trials in non-infectious uveitis, with median time to treatment failure above 48 weeks against about 12 weeks on placebo. A supplemental application to expand the label is planned for the first half of 2027. Mosliciguat, from the Pulmovant unit, cut pulmonary vascular resistance by 56.3% against placebo in a Phase 2 trial in pulmonary hypertension linked to lung disease, and a Phase 3 study has started.

Cash, Litigation and Risks

Roivant Sciences (NASDAQ:ROIV) has one of the strongest balance sheets among mid-cap biotechs, with about USD 4.2 billion of cash and securities. That includes a USD 950 million payment received in July from a lipid nanoparticle Patent settlement worth up to USD 2.25 billion, with a further USD 1.3 billion contingent on an appeal heard on November 5, 2026. The company says its cash runway extends into profitability. Risks include the pace of the LISRAYA launch after early stocking, competition in autoimmune markets, the mixed dose response in the IMVT-1402 study and the outcome of the appeal. Immunovant has also stopped a cutaneous lupus study. Investors will watch fourth-quarter LISRAYA sales, FDA feedback on IMVT-1402 in rheumatoid arthritis, the appeal decision and the company's investor day on December 9, 2026.

Where Things Stand

Roivant Sciences (NASDAQ:ROIV) reported USD 31.0 million of LISRAYA sales in five weeks, a strong start for its first major launch, alongside positive rheumatoid arthritis and uveitis data and about USD 4.2 billion in cash. Net loss was USD 191.6 million, including one-time distributions. A further USD 1.3 billion of settlement money depends on an appeal. Fourth-quarter sales and the December 9 investor day are the next checkpoints.